The Publication Digests section of this Learning Zone provides simplified detail and graphical summaries of the latest published research on glaucoma treatments.
The peer-reviewed article in this section describes:
- a phase 4 double-blind trial to evaluate the effect of brinzolamide 1%/brimonidine 2% fixed-dose combination as an adjunct to a prostaglandin analogue in patients with open angle glaucoma or ocular hypertension
Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension
The trial showed that twice daily administration of brinzolamide/brimonidine fixed-dose combination in addition to a prostaglandin analogue (PGA) resulted in a significantly greater reduction in mean diurnal intraocular pressure than PGA monotherapy in patients with open-angle glaucoma or ocular hypertension.
This content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.